Roivant Sciences News - August 2026
Roivant Announces FDA Approval for LISRAYA™, a New Dermatomyositis Treatment
Roivant Sciences announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) for the treatment of adults with...
Roivant Secures FDA Approval for First Targeted Dermatomyositis Therapy
The U.S. Food and Drug Administration (FDA) approved LISRAYA (brepocitinib) for adults with dermatomyositis. Roivant Sciences' subsidiary, Priovant...
Roivant's first quarter EPS beats estimates on lower-than-expected loss, while its cash position remains strong at $3.9B.
Roivant Sciences reported a first quarter net loss of $0.26 per share, narrower than analyst expectations, on revenue of $1.4 million which missed estimates....
Roivant Sciences Ltd Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Roivant Sciences is projected to report a Q2 2026 revenue of approximately $2.00 million and a consensus EPS loss of -$0.45, while its current stock price of...